New antibody drug aims to rally immune system against Hard-to-Treat cancers
NCT ID NCT05808634
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial is testing a new drug called BA3182 in 168 people with advanced adenocarcinoma, a type of cancer that has spread and cannot be removed by surgery. The drug is a bispecific antibody designed to bring immune cells close to cancer cells so they can be destroyed. The main goals are to check the drug's safety and see if it can shrink tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- BA3182 (a bispecific antibody that helps immune cells target and attack cancer cells)
- What this could lead to
- If successful, this could point toward a new treatment option for advanced adenocarcinoma that is resistant to other therapies.
- What could go wrong
- This is an early Phase 1 trial with only 168 participants, so the drug may not prove effective or safe enough to move forward. Side effects from immune activation could be significant.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fred Hutch Cancer Center
RECRUITINGSeattle, Washington, 98109, United States
-
Karmanos Cancer Institute
RECRUITINGDetroit, Michigan, 48201, United States
-
Northwestern University
RECRUITINGChicago, Illinois, 60611, United States
Contact Email: •••••@•••••
-
The Christ Hospital Cancer Center
RECRUITINGCincinnati, Ohio, 45219, United States
-
UC Irvine
RECRUITINGIrvine, California, 92697, United States
Contact Email: •••••@•••••
-
USC Norris Comprehensive Cancer Center
RECRUITINGLos Angeles, California, 90033, United States
-
University Hospitals Cleveland Medical Center
RECRUITINGCleveland, Ohio, 44106, United States
-
University of Illinois
RECRUITINGChicago, Illinois, 60612, United States
-
Yale Cancer Center
RECRUITINGNew Haven, Connecticut, 06511, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.